Tower Research Capital LLC TRC Has $1.79 Million Stock Holdings in Illumina, Inc. (NASDAQ:ILMN)

Tower Research Capital LLC TRC boosted its stake in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 188.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,373 shares of the life sciences company's stock after purchasing an additional 8,739 shares during the quarter. Tower Research Capital LLC TRC's holdings in Illumina were worth $1,787,000 at the end of the most recent quarter.

Several other hedge funds have also made changes to their positions in the stock. Transatlantique Private Wealth LLC bought a new stake in shares of Illumina in the 4th quarter valued at approximately $215,000. MML Investors Services LLC raised its position in shares of Illumina by 10.8% during the fourth quarter. MML Investors Services LLC now owns 25,888 shares of the life sciences company's stock worth $3,459,000 after acquiring an additional 2,515 shares during the last quarter. Natixis bought a new position in Illumina in the fourth quarter valued at about $174,000. MetLife Investment Management LLC increased its position in Illumina by 8.6% in the fourth quarter. MetLife Investment Management LLC now owns 89,418 shares of the life sciences company's stock worth $11,949,000 after purchasing an additional 7,083 shares during the period. Finally, BI Asset Management Fondsmaeglerselskab A S raised its holdings in Illumina by 170.7% during the 4th quarter. BI Asset Management Fondsmaeglerselskab A S now owns 42,404 shares of the life sciences company's stock worth $5,666,000 after purchasing an additional 26,737 shares during the last quarter. Institutional investors own 89.42% of the company's stock.

Illumina Stock Down 0.3 %

Shares of ILMN stock traded down $0.26 on Friday, hitting $77.35. 1,424,483 shares of the stock were exchanged, compared to its average volume of 2,280,770. The company has a current ratio of 1.77, a quick ratio of 1.42 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $12.24 billion, a P/E ratio of -10.07, a price-to-earnings-growth ratio of 1.60 and a beta of 1.38. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $156.66. The business has a 50-day moving average of $82.02 and a 200 day moving average of $118.20.

Illumina (NASDAQ:ILMN - Get Free Report) last released its quarterly earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share for the quarter, missing analysts' consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. Equities analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

Analyst Upgrades and Downgrades

Several equities research analysts have recently commented on ILMN shares. Robert W. Baird lowered their price target on shares of Illumina from $127.00 to $90.00 and set a "neutral" rating for the company in a research report on Wednesday, March 5th. Guggenheim dropped their target price on shares of Illumina from $170.00 to $150.00 and set a "buy" rating for the company in a research report on Friday, February 7th. Canaccord Genuity Group reduced their price target on Illumina from $135.00 to $115.00 and set a "hold" rating on the stock in a research report on Tuesday, March 11th. Citigroup decreased their price objective on Illumina from $90.00 to $85.00 and set a "neutral" rating for the company in a research note on Monday, April 7th. Finally, Royal Bank of Canada cut their target price on Illumina from $128.00 to $112.00 and set an "outperform" rating on the stock in a research note on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $138.70.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.